Contents

amfAR in 2016 01

Grants, Fellowships, and Awards 07

Research Grants, Fellowships, and Awards
TREAT Asia Grants and Awards
GMT Initiative Awards
Public Policy Awards

Financial Highlights 13

Leadership and Advisory Committees 15

Board of Trustees
Scientific Advisory Committee
Program Advisory Council
Management Group

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
Countdown to a Cure for AIDS

In 2015, amfAR announced a $100 million investment strategy to support its Countdown to a Cure for AIDS initiative, which is aimed at developing the scientific basis for a cure by 2020. The strategy represents an unprecedented expansion of amfAR’s grant making and is designed to provide support to any scientist or team of investigators for any research idea with the potential to advance the search for a cure, at any stage of its development.

In just the first 24 months of the initiative, amfAR has supported 139 principal investigators and key personnel in 16 U.S. states and nine other countries around the world. Structured to provide sustained support for a wide range of studies that advance both emerging and established ideas, the strategy comprises the following components:

- **The amfAR Institute for HIV Cure Research**, established in 2016 with a $20 million grant over five years to the University of California, San Francisco (UCSF), is the cornerstone of amfAR’s cure research efforts.
- **Innovation Grants**, two-year awards of up to $200,000 each that enable researchers to test innovative ideas supported by limited preliminary data.
- **Impact Grants** of up to $2 million each over four years support the in-depth development of concepts already underpinned by preliminary data showing genuine potential for achieving a cure.
- **Investment Grants** are aimed at recruiting the experience and expertise of scientists from outside the field of HIV. These $1 million grants are awarded over a four-year period. Grantees may have expertise in fields such as cancer, neuroscience, or inflammatory disease that can directly inform efforts to cure HIV.
- **ARCHE**, the amfAR Research Consortium on HIV Eradication, was launched in 2010. It supports collaborative teams of scientists in the U.S. and around the world working on a range of HIV cure strategies.
- **The Opportunity Fund** is a funding mechanism that enables amfAR to respond quickly to emerging and unforeseen research opportunities.

Innovation Grants

In June 2016, amfAR announced a new round of Innovation Grants, totaling close to $1.4 million, to allow scientists to better understand why HIV persists in the body despite effective antiretroviral therapy and pursue novel pathways to a cure. The grants were supported in part by the Foundation for AIDS and Immune Research (FAIR).

Among the grantees are Dr. Jonathan Karn of Case Western Reserve University in Cleveland, who is aiming to develop a more accurate, cost-effective, and efficient way to measure the size of the viral reservoir; Dr. Maud Mavigner of Emory University in Atlanta, who is conducting a comprehensive study to identify the most accurate methods to measure the viral reservoir in rhesus macaques infected with SIV (the simian form of HIV); and Dr. Celsa Spina of the University of California, San Diego, who is studying how and where HIV inserts itself into our DNA, enabling it to establish the hidden viral reservoir.

Investment Grants

In January 2016, amfAR awarded $1 million each over four years to Harvard physicist Dr. David Weitz and bioengineer and polymer scientist Dr. Alexander Zelikin of Aarhus University in Denmark. The two are collaborating with leading HIV researchers Drs. Bruce Walker and Martin Tolstrup at Harvard and Aarhus, respectively, in
their efforts to eradicate the viral reservoir, which is considered the principal barrier to curing HIV.

**ARCHE (amfAR Research Consortium on HIV Eradication)**

In October 2015, amfAR provided $850,000 of renewal ARCHE funding to a consortium of European researchers who aim to replicate the case of the “Berlin patient,” the first and only person known to have been cured of HIV. Diagnosed with leukemia, the patient was given a stem cell transplant with a twist: the cells he received were taken from a donor with a rare genetic mutation conferring resistance to HIV infection. Led by Dr. Javier Martinez-Picado of IrsiCaixa in Spain and Dr. Annemarie Wensing of University Medical Center Utrecht in the Netherlands, the team has already identified a group of patients who have undergone transplants and continues to monitor their progress in the hopes of generating new knowledge that can inform more widely applicable interventions.

amfAR also awarded a $672,000 ARCHE grant in June 2016 to support a research team led by Dr. Timothy Schacker of the University of Minnesota, Minneapolis. Schacker is collaborating with a pair of leading investigators from the amfAR Institute for HIV Cure Research, Drs. Steven Deeks and Peter Hunt of the University of California, San Francisco (UCSF), to address one of the greatest challenges in HIV cure research: how to establish whether a person has been cured.

**Mathilde Krim Fellowships**

In October 2015, amfAR awarded a total of $600,000 in Mathilde Krim Fellowships in Basic Biomedical Research, which provide funding for exceptional young researchers who are new to the field of HIV/AIDS research. The program, which was created in 2008 in honor of amfAR’s Founding Chairman Dr. Mathilde Krim, has achieved spectacular results, including numerous published studies in major scientific journals. Each Krim Fellow receives $150,000 over two years.

The 2016 fellows are Dr. Luis Agosto of Boston Medical Center, who is exploring one of the mechanisms that perpetuates the viral reservoir, with the goal of understanding how the virus evades the immune system; Dr. Liang Shan of Yale University, who is using a humanized mouse model to test the efficacy of latency reversing drugs, studying their ability to reactivate HIV so that the immune system can kill those cells that harbor the virus; Dr. Louise Scharf of the California Institute of Technology in Pasadena, who is studying the molecular structure of broadly neutralizing antibodies isolated from two HIV-infected patients to better understand how these powerful antibodies can help in the development of a vaccine against the virus; and Dr. Amit Sharma of the Fred Hutchinson Cancer Research Center in Seattle, who is investigating how rhesus macaques can be better utilized as an animal model in HIV vaccine studies.

**HIV Cure Summit**

In December 2015, amfAR held its second annual HIV Cure Summit at the University of California, San Francisco (UCSF), where leading amfAR-funded HIV cure researchers reported on their progress and discussed the scientific challenges that continue to stand in the way of a cure. The summit followed a November 30 press conference announcing the establishment of the amfAR Institute for HIV Cure Research with a $20 million grant over five years to UCSF. Speaking at the summit, Drs. Warner Greene, Mike McCune, Satish Pillai, and Steven Deeks addressed the four pillars of HIV cure research: charting the locations of latent HIV reservoirs; understanding how these pockets of virus are established and maintained; recording the amount of virus they contain; and finding a way to eliminate them.

Dr. Javier Martinez-Picado of IrsiCaixa in Spain

amfAR Institute for HIV Cure Research scientist Dr. Nadia Roan of the University of California, San Francisco (UCSF)
Think Tanks

In March 2016, amfAR hosted a think tank in Memphis, TN, on measuring the latent HIV reservoir. One of the central challenges in determining whether a person has been cured is measuring small amounts of virus in difficult-to-find niches. The researchers discussed multiple approaches to address the issue and helped design a project that amfAR funded in June 2016, which is being led by think tank participant Dr. Timothy Schacker of the University of Minnesota, Minneapolis.

amfAR hosted another think tank in Portland, OR, in June 2016, on gene therapy approaches to curing HIV. While pharmacological and immunological approaches remain the dominant cure strategies, the case of the “Berlin patient”—the first and only person known to have been cured of HIV—points to the promise of gene therapy. The 10 researchers discussed the various gene therapy strategies currently being pursued and developed recommendations for further advancing the field.

TREAT Asia

amfAR’s TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) program is a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV treatments to adults and children across the Asia-Pacific through research, education, and advocacy of evidence-based HIV-related policies. The TREAT Asia Network encompasses 21 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. TREAT Asia scientists produced a record 34 publications in peer-reviewed medical journals in 2016.

Gathering Critical Information

TREAT Asia pioneered the region’s first adult observational database for HIV/AIDS—the TREAT Asia HIV Observational Database (TAHOD)—which now includes anonymous data collected from approximately 10,000 patients at 21 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. The TAHOD-Lite database, launched by TREAT Asia in 2015, includes more basic data but from a much larger proportion of the HIV-positive patients seen at participating sites.

A Global Collaboration

For the past 10 years, amfAR’s TREAT Asia program has been leading the Asia-Pacific region’s involvement in the U.S. National Institutes of Health’s (NIH’s) global HIV consortium, IeDEA—the International Epidemiologic Databases to Evaluate AIDS. In 2016, amfAR successfully re-competed for funding for a new five-year cycle. Studies will be conducted across 58 institutions in 13 countries to address emerging and critical issues facing people living with HIV who are transitioning from pediatric to adolescent care, and aging into older adults.

The new funding will also expand TREAT Asia’s research portfolio to evaluate mental health issues for adolescents, explore how amphetamine use impacts HIV risk behaviors among men who have sex with men and transgender individuals, and enhance the use of eHealth technologies to engage and retain people in treatment programs.

Improving Care for Children

TREAT Asia’s Pediatric Network includes 20 sites in six countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database was modeled on the adult database and includes data from more than 6,400 pediatric patients in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam.

Adolescent Research

There has been growing recognition that the global HIV community has not done enough to prepare patients, families, and providers for the transition of children into adult life and from pediatric to adult HIV care. TREAT Asia is helping to develop and fund adolescent transition programs with the Children and Youth Program of SEARCH (South East Asia Research Collaboration on HIV) at the Thai Red Cross AIDS Research Centre (TRC-ARC) with additional funding from LIFE+ and the International AIDS Society’s Collaboration on Paediatric HIV Education and Research (CIPHER) initiative. In 2016, TREAT Asia/amfAR was awarded a two-year Developmental Research Grant by the National Institutes of Health (NIH) to improve the collection of data on adolescent transition in Malawi, South Africa, and Thailand.

In 2016, three TREAT Asia investigators, Drs. Tavitiya Sudjaritruk, Suvaport Anugulruengkitt, and Watsamon Jantarabenjakul, were awarded prestigious grants under the CIPHER initiative to research medical problems experienced by HIV-positive youth. In addition, Dr. Nadia Kancheva-Landolt of HIV-NAT at the TRC-ARC conducted several studies aimed at improving the reproductive health of HIV-positive young women in Thailand, with funding from ViiV Healthcare. TREAT Asia has also been following 248 HIV-infected adolescents at nine sites in Malaysia, Thailand, and

Participants at the May 2016 hepatitis C and HIV co-infection treatment training in Bangkok
Vietnam to evaluate social, cultural, and behavioral factors that affect treatment adherence. The study, which is being funded by LIFE+*, uses an audio computer-assisted self-interview instrument.

Expanding Pre-Exposure Prophylaxis (PrEP) in Thailand

In 2016, amfAR funded a study to assess combination HIV prevention needs, including pre-exposure prophylaxis (PrEP) among female sex workers in Bangkok and Pattaya, Thailand. The research team brings together experts from the Service Workers in Group (SWING) Foundation, a Thai advocacy organization for sex workers; Institute for Population and Social Research at Mahidol University in Bangkok; Johns Hopkins Bloomberg School of Public Health; and amfAR.

Addressing Unmet Needs in HIV Care

In January 2016, TREAT Asia embarked on a think tank project to identify and address gaps in the management of HIV in Asia. The project includes over 20 experts in HIV and other sub-specialties from a dozen countries in the region. The think tanks are focusing on three priority areas: HIV and cardiovascular disease, HIV and liver disease, and HIV and drug resistance.

Mobilizing HIV-Positive Youth

In February and May 2016, TREAT Asia held two Youth ACATA (Asia Community for AIDS Treatment and Advocacy) workshops in Bangkok for young people living with HIV from Cambodia, Indonesia, and Thailand. Launched in 2015 with support from ViiV Healthcare’s Positive Action for Adolescents program, Youth ACATA aims to educate participants about HIV and antiretroviral therapy and connect them to other HIV-positive youth in the region.

Promoting Treatment Access for GMT

In late 2015, with partial funding from amfAR, the Thai Red Cross AIDS Research Centre launched the Adam’s Love Clinic for gay men, other men who have sex with men, and transgender individuals (collectively, GMT), as well as the Tangerine Community Health Centre—Southeast Asia’s first transgender-specific sexual health clinic—both in Bangkok.

Taking on Hepatitis C Co-Infection

In May 2016, TREAT Asia co-sponsored a training session in Bangkok for clinicians on treating hepatitis C and HIV co-infection with direct-acting antivirals. TREAT Asia conducted the training in collaboration with the International Network for Hepatitis in Substance Users and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine. In August 2016, TREAT Asia hosted its fourth regional strategic meeting on hepatitis C virus treatment access with 22 participants from key population regional networks in eight Asian countries.

Public Policy

Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. Through its Public Policy Office in Washington, DC, amfAR educates policymakers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world.

Shaping the Domestic Response to HIV/AIDS

In February 2016, amfAR published an infographic titled *Small Increase, Big Impact*, illustrating the declining purchasing power of the National Institutes of Health’s (NIH) HIV/AIDS research dollars. In 2016, the NIH budget was increased by $2 billion, and President Obama proposed a further increase of $825 million for 2017. However, HIV research funding remained at 2015 levels. An increase in HIV research funding in line with the increase in total NIH funding would have meant an additional $76.6 million for HIV research for 2017. Such an increase would have allowed the NIH to fund 180 HIV/AIDS studies that could significantly advance HIV prevention, treatment, or cure research; 51 clinical trials focused on curing HIV; or a breakthrough prevention trial.

Key Populations

amfAR is dedicated to addressing the needs of the people most vulnerable to HIV infection: men who have sex with men, sex workers, people who inject drugs, and transgender individuals. In October 2015, amfAR published *Towards Defining an HIV Implementation Science Agenda for Key Populations in Low- and Middle-Income Countries* based on a meeting the Foundation hosted in May 2015 to brainstorm how implementation science
research might improve HIV outcomes for key populations in resource-limited settings. amfAR published Following the Money to Key Populations, National Priorities, and Evidence-Based Budgeting in June 2016. This report is a qualitative assessment of how Kenya and South Africa use health data for budgetary resource allocation.

In July 2016, amfAR published Is PEPFAR Funding for Key Populations Aligned with the Epidemiologic Burden? This report is based on an evaluation of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Worldwide, 40–50% of all HIV infections in adults aged 15–49 occur among key populations. The report concluded that the disproportionate HIV risk, along with poor quality health services, underscores the continuing importance of prioritizing resources and targeted interventions.

Global Health

In FY2016, amfAR published The World Without PEPFAR, an infographic highlighting significant advances in global HIV/AIDS treatment and prevention made possible by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Launched in 2003, PEPFAR made billions of dollars available for HIV programs in developing countries and fundamentally changed the course of the global epidemic.

amfAR also added new features and data to its PEPFAR Country/Regional Operational Plan database, a comprehensive, navigable database of PEPFAR’s planned funding of HIV/AIDS activities from 2007 to 2015. Launched in 2015, the database is designed to help civil society organizations, ministries of health and finance, researchers, and other stakeholders access and understand PEPFAR’s programs and priorities on a deeper level than was possible using other platforms.

The GMT Initiative

Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men, and transgender individuals (collectively, GMT) throughout the developing world through its GMT Initiative. Through small, targeted grants to grassroots groups, amfAR has expanded access to HIV education and prevention services; supported advocacy aimed at increasing funding for prevention and treatment services; and worked to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.

Implementation Science Awards

In FY2016, amfAR’s grant making through the GMT Initiative evolved to support larger implementation science projects aimed at identifying barriers to HIV testing, treatment, and care and studying the impact of innovative HIV service delivery models for GMT in low- and middle-income countries. amfAR has awarded $2.6 million over three years to support three such studies.

Dr. Chris Beyrer of Johns Hopkins University is leading a team of researchers and community-based services (in collaboration with the International HIV/AIDS Alliance Myanmar) in evaluating the effectiveness of promising interventions for GMT in Myanmar, where increased HIV testing and treatment opportunities are becoming available. The researchers are assessing the effectiveness of HIV self-testing done in the privacy of one’s home, point-of-care CD4 testing, and the use of “peer navigators” familiar with the local health system to help those newly diagnosed gain access to HIV treatment and care.

In Lima, Peru, Dr. Javier Lama of Asociación Civil Impacta Salud Educación and his team are aiming to improve the continuum of care among transgender women by using an innovative model that integrates HIV prevention and treatment services with transgender-affirming medical care.

And in Bangkok, Dr. Nittaya Phanuphak and her team at the Thai Red Cross AIDS Research Centre are working to show how innovative technologies such as GMT-targeted websites that incorporate online counseling and support can be utilized to increase rates of HIV testing and referrals to prevention and treatment programs.

amfAR HIV Scholars Program

In FY2016, amfAR supported four young researchers from Paraguay, Brazil, South Africa, and Indonesia undergoing five months of graduate-level public health study at the Center for LGBT Health Research at the University of Pittsburgh Graduate School of Public Health as part of the amfAR HIV Scholars Program. The program aims to strengthen GMT community-based research and responses to HIV, often in areas where little data about HIV among GMT currently exist and where stigma and discrimination deter many from seeking HIV testing and services. The 2016 amfAR HIV Scholars are Dr. Antonio Spagnolo of the National University of Asunción in Paraguay; Daniel Dutra de Barros of Santa Casa de São Paulo School of Medical Sciences in Brazil; Kabelo Maleke of Project Boithato at the Anova Health Institute in rural South Africa; and Adi Nugroho of the GWL-INA Network in Jakarta, Indonesia.

Public Information

amfAR seeks to translate and disseminate information on important HIV/AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to increase broad awareness and knowledge of the pandemic. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policymakers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for HIV.
amfAR produces a range of periodicals in both print and electronic formats, including its newsletter *Innovations*, published twice a year and distributed to more than 45,000 people; the *TREAT Asia Report*, an email newsletter distributed six times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to nearly 100,000 people. The Foundation’s website, which attracts an average of 40,000 visitors per month, features news, interviews, and original articles covering HIV/AIDS research, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policymakers, healthcare professionals, people living with HIV/AIDS, and the general public.

**Social Media**

amfAR has vigorously expanded its presence in the social media arena, reaching large numbers of people, including a younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly adds content to its Facebook page, live tweets from events, and posts images on Instagram from fundraising and program events. amfAR has 72,000 likes on Facebook, 40,000 Twitter followers, and more than 108,000 Instagram followers.

**Media Outreach**

In 2016, amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of HIV/AIDS-related press coverage. Articles and reports involving amfAR—many of which included interviews with amfAR staff and spokespeople—were carried in numerous media outlets, including *The New York Times*, *Forbes*, *The Advocate*, the *South China Morning Post*, CBS Radio, Reuters, and Bloomberg News.

amfAR’s public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation’s mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, amfAR’s Founding International Chairman, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Campaign Chair Sharon Stone.

Other celebrity supporters included amfAR Ambassadors Milla Jovovich, Michelle Yeoh, and Cheyenne Jackson, Kathy Bates, Angela Bassett, Julia Roberts, Matt Bomer, Jamie Lee Curtis, Diane von Furstenberg, Gwyneth Paltrow, Chiara Ferragni, Ryan Murphy, Lady Gaga, Diane Kruger, Uma Thurman, Dame Helen Mirren, Faye Dunaway, Katy Perry, Kate Moss, Marc Jacobs, Ricky Martin, Lea Michele, Michelle Rodriguez, Whoopi Goldberg, amfAR Trustee Harry Belafonte, Naomi Campbell, Heidi Klum, Riccardo Tisci, Adrien Brody, Eva Longoria, Harvey Keitel, Leonardo DiCaprio, Robert De Niro, Robin Thicke, Andrea Bocelli, Dean and Dan Caten, Chris Tucker, Jennifer Garner, Donatella Versace, and Carine Roitfeld.

In 2016, a collection of 1980s classic hits was updated by contemporary artists for *The Time is Now!*—a 14-track compilation album to benefit amfAR. The album features a soulful rendition of Michael Jackson’s “Billie Jean” by singer-songwriter Aloe Blacc, and a rendition of New Order’s “Bizarre Love Triangle” performed by Sugar for Sugar, consisting of Scarlett Johansson, Julia Haltigan, Holly Miranda, and Kendra Morris. The band Lower Dens, pop rock group DNCE, Dita Von Teese and Sebastien Tellier, and songwriting duo Marian Hill are also featured on the album.
2016 RESEARCH GRANTS, FELLOWSHIPS, AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

Supported in part with funds provided by the FAIR Foundation

amfAR INSTITUTE FOR HIV CURE RESEARCH

Principal Investigator: Paul Volberding, MD
University of California, San Francisco
San Francisco, CA
$20,000,000

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Predictors of time to viremia with an analytic treatment interruption
Principal Investigator: Timothy Schacker, MD
University of Minnesota
Minneapolis, MN
$671,846

Allogeneic stem cell transplant in HIV-1-Infected Individuals
Principal Investigator: Annemarie Wensing, MD, PhD
University Medical Center Utrecht
Utrecht, The Netherlands
$849,910

Development of a humanized superagonist antibody to human IL-21 for HIV cure
Principal Investigator: Di Yu, PhD
Monash University
Clayton, Australia
$225,512

INVESTMENT GRANTS

Eradicating the HIV reservoir: Using microfluidics to exploit killer T cells
Principal Investigator: David Weitz, PhD
Harvard University
Cambridge, MA
$977,114

Tandem latency reversal and suicide prodrugs to eliminate HIV reservoirs
Principal Investigator: Alexander Zelkin, PhD
Aarhus University
Aarhus, Denmark
$982,519

INNOVATION GRANTS

Analytic treatment interruption to study viral reservoirs and as test for cure in HIV-infected adults on ART
Principal Investigator: Steven Deeks, MD
University of California, San Francisco
San Francisco, CA
$77,764

Uncovering HIV-1-infected cells: a new path towards a cure
Principal Investigator: Andrés Finzi, PhD
Université de Montréal, Centre de Recherche du CHUM
Montreal, Canada
$199,997

Hormonal control of latent HIV proviruses
Principal Investigator: Jonathan Karn, PhD
Case Western Reserve University
Cleveland, OH
$200,000

Optimized assays to measure the latent SIV reservoir in rhesus macaques on ART
Principal Investigator: Maud Mavigner, PhD
Emory University
Atlanta, GA
$200,000

Mechanisms and correlates of post-ART treatment control in SIV-infected macaques
Principal Investigator: Mirko Paiardini, PhD
Emory University
Atlanta, GA
$200,000

Genomic locations of HIV proviruses responsive to latency reversing agents
Principal Investigator: Celsa Spina, PhD
University of California, San Diego
San Diego, CA
$200,000

Discovery of tools to modify the fate of uracilated HIV DNA in macrophages
Principal Investigator: James Stivers, PhD
Johns Hopkins University
Baltimore, MD
$200,000

MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCH

HIV cell-to-cell transmission and the establishment of latency
Principal Investigator: Luis Agosto, PhD
Boston Medical Center
Boston, MA
$150,000

Rational immunogen design based on study of potent HIV-1 trimer-specific bNAb
Principal Investigator: Louise Scharf, PhD
California Institute of Technology
Pasadena, CA
$150,000

Identification, reactivation and elimination of latent HIV-1 in humanized mice
Principal Investigator: Liang Shan, PhD
Yale University
New Haven, CT
$150,000

Determants of HIV-1 replication in non-human primate models
Principal Investigator: Amit Sharma, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA
$146,829

PHASE II KRIM FELLOWSHIP GRANTS

Optimization of anti-HIV antibodies for prevention and therapy
Principal Investigator: Stylianos Bournazos, PhD
The Rockefeller University
New York, NY
$80,000

Identification of transmitted viral determinants of HIV pathogenesis
Principal Investigator: Dario Delfinia, PhD
Emory University
Atlanta, GA
$50,000

Identification of a novel HIV-1 restriction factor induced by RNA sensing
Principal Investigator: Henning Hofmann, PhD
Robert Koch Institute
Berlin, Germany
$80,000

Targeting engineered nanoparticles for therapeutic purge of HIV-1 reservoir
Principal Investigator: Nuria Izquierdo-Úsersos, PhD
Fundación IrsiCaixa
Barcelona, Spain
$50,000

SCIENTIFIC MEETINGS

Conference on Cell & Gene Therapy for HIV Cure (2016)
Principal Investigator: Keith Jerome, MD, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA
$10,000

International AIDS Conference 2016
Principal Investigator: Owen Ryan, MPH, MIA
International AIDS Society
Geneva, Switzerland
$50,000
2016 TREAT ASIA GRANTS AND AWARDS

All projects listed below were awarded funding during the period October 1, 2015, through September 30, 2016.

1 Supported by National Institutes of Health cooperative agreement number U01AI069907 with funds from the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse

2 Supported by National Institutes of Health grant number R01HD073972 funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development

3 Supported with funds provided by the AIDS Life Association

4 Supported with funds provided by the Open Society Foundations

5 Supported with funds provided by ViV Healthcare

AUSTRALIA

AUSTRALIA HIV OBSERVATIONAL DATABASE (AHOD) SITES

O’Brien Street Practice
Adelaide, South Australia
William Donohue, MBBS
$1,575

Sexual Health and HIV Service In Metro North
Brisbane, Queensland
Diane Rowling, MBBS, RACP, FACHSHM
$3,600

Cairns Sexual Health Service
Cairns, Queensland
Darren Russell, MD
$5,250

RPA Sexual Health Clinic
Camperdown, New South Wales
David Templeton, MBChB, PhD
$675

Monash Health - Clayton
Clayton, Victoria
Ian Woolley, MBBS, FRACP
$5,475

D.A. Ellis Pty., Ltd.
Coffs Harbour, New South Wales
David Ellis, MBBS
$675

East Sydney Doctors
Darlinghurst, New South Wales
David Baker, MB, ChB, Dip Med, DCH
$7,050

Holdsworth House Medical Practice
Darlinghurst, New South Wales
Mark Bloch, MD
$5,925

St. Vincent’s Hospital Sydney
Darlinghurst, New South Wales
David A. Cooper, MD
$5,475

Taylor Square Private Clinic
Darlinghurst, New South Wales
Robert Finlayson, MBBS, DipVen, FACHSHM
$5,025

Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program
Darwin, Northern Territory
Manoji Gunathilake, MD, MBBS, FACHSHM
$975

Gladstone Road Medical Centre
Highgate Hill, Queensland
David Orth, MBBS, DipVen
$5,100

Nepean Blue Mountains Local Health District, Blue Mountains Sexual Health and HIV Clinic
Katoomba, New South Wales
Eva Jackson, MBBS, FACHSHM
$1,575

Nepean Blue Mountains Local Health District, Nepean Sexual Health Clinic
Kingswood, New South Wales
Julian Langton-Lockton, MBBS
$1,350

Sexual Health and AIDS Services (SHAIDS)
Lismore, New South Wales
David Smith, MBBS, DipVen, FACHSHM, GrapDip BA
$6,075

Melbourne Sexual Health Centre
Clayton, Victoria
Tim Read, MBBS, DipVen, FRACGP, FACHSHM, EpiDip
$4,425

Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital
Melbourne, Victoria
Jennifer Hoy, MBBS
$5,550

Sunshine Coast Hospital and Health Service
Nambour West, Queensland
David Bowden, MBBS
$6,375

Northside Clinic (Vic) Pty Ltd
North Fitzroy, Victoria
Richard Moore, MBBS
$7,500

Royal Perth Hospital
Perth, Western Australia
David Nolan, MBBS, FRACP, PhD
$5,175

Prahran Market Clinic Pty., Ltd.
Prahran, Victoria
Norman Roth, MBBS FACHSHM
$5,775

Sydney Sexual Health Centre, Sydney Hospital
Sydney, New South Wales
Caroline Thng, MBBS, MRCP
$4,275

Clinic 468, HINE Sexual Health, Hunter New England Local Health District
Tamworth NEMSC, New South Wales
Nathan Ryder, MD
$900

Illawarra Shoalhaven Local Health District
Warragong, New South Wales
Katherine Brown, MD
$1,350

UNSW-Sydney
Sydney, New South Wales
Matthew G. Law, PhD

IeDEA Asia-Pacific Research Collaboration: TREAT Asia HIV Observational Database & Australia HIV Observational Database
$256,385

IeDEA Asia-Pacific Research Collaboration: HIV and aging in TAHOD-LITE
$15,000

IeDEA Asia-Pacific Research Collaboration: Cancer Studies
$135,922

IeDEA Asia-Pacific Research Collaboration: TREAT Asia Pediatric HIV Observational Database
$175,225

Effectiveness and tolerability of hepatitis C treatment in HIV co-infected patients in routine care services in Asia
$19,289

CAMPBODIA

National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health
Phnom Penh

Ly Penh Sun, MD, MSc
TREAT Asia HIV Observational Database (TAHOD)
$20,000

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$33,666

TREAT Asia Pediatric HIV Observational Database (TAPHOD)
$25,000

New Hope for Cambodian Children
Kileen, TX

John Tucker
Our Village
$20,743

Our Village and New Hope House
$50,000

CHINA

Beijing Ditan Hospital
Beijing

Fuje Zhang, MD, MSPH, PhD
TREAT Asia HIV Observational Database (TAHOD)
$16,000

Queen Elizabeth Hospital
Hong Kong

Man Po Lee, MBBS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,030

8
INDIA

Johns Hopkins University at B.J. Medical College and Sassoon General Hospital
Pune
Vidya Mave, MD, MPH
Epidemiology of HIV/AIDS and associated comorbidities in a public antiretroviral treatment (ART) clinic in Pune, India
$150,000

Chennai Antiviral Research and Treatment Clinical Research Site, YRG CARE Medical Centre, VHS Chennai
Nagalingeswaran Kumarasamy, MBBS, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,040

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$5,000

TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$7,500

Institute of Infectious Diseases
Pune
Sanjay Pujari, MD, AAHIVS, MBBS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,440

Wide Angle Social Development Organization
Imphal
Rajkumar Nalinikanta
Improving HBV & HCV prevention & treatment access in Manipur-Phase IV
$10,060

INDONESIA

Cipto Mangunkusumo General Hospital
Jakarta
Nia Kurniati, MD
TREAT Asia HIV Observational Database (TAP-HOD)
$7,500

Evy Yunihastuti, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,440

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$5,000

Indonesia AIDS Coalition
Jakarta
Aditya Wardhana
Hep C – Know it, get tested and beat it!
$6,583

Sanglah Hospital, Udayana University School of Medicine
Denpasar, Bali
Tuti Parwati Merati, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,440

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$28,264

Ketut Dewi Kumara Wati, MD
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$7,500

Persaudaraan Korban Napza Indonesia (PKNI)
Jakarta
Edo Agustian
Increasing awareness of hepatitis C with 360 short movie campaign
$2,500

JAPAN

National Center for Global Health and Medicine
Tokyo
Junko Tanuma, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$18,000

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$2,000

MALAYSIA

Hospital Likas
Kota Kinabalu
Fong Siew Mey, MBBS
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$7,500

Hospital Raja Perempuan Zainab II
Kota Bharu
Nik Khairulddin Nik Yusoff, MBBS
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$7,500

Pediatric Institute, Hospital Kuala Lumpur
Kuala Lumpur
Thahira A. Jamal Mohamed, MBBS
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$7,500

Penang Hospital
Georgetown
Revathy Nallusamy, MBBS
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$2,000

Sungai Buloh Hospital
Sungai Buloh
Yasmin Mohamed Gani, MD
Study of Transitioning Asian Youth (STAY) Cohort
$14,561

Benedit Lim Heng Sim, MBBS, MRCP
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$16,130

University of Malaya
Kuala Lumpur
Raja Iskandar Shah Raja Azwa, MBBS
Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$45,361

Adeeba Kamarulzaman, MBBS, FRACP, FAMM, FASc
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,390

Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment
$7,581

NEPAL

Union C
Kathmandu
Roshan Sapkota
National Awareness Campaign-NEPAL
$7,001

PHILIPPINES

Research Institute for Tropical Medicine
Muntinlupa City
Rossana Ditangco, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$22,640

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$5,950

SINGAPORE

Tan Tock Seng Hospital
Singapore
Oon Tek Ng, MBBS
TREAT Asia HIV Observational Database (TAHOD)
$19,250

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$2,000

SOUTH KOREA

Yonsei University College of Medicine
Seoul
Jun Yong Choi, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$18,290

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2)
$2,000

TAIWAN

Taipei Veterans General Hospital
Taipei City
Wing-Wai Wong, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,670

THAILAND

Chiang Mai University – Research Institute for Health Sciences
Chiang Mai
Linda Aurpibul, MD
Long-term HBV treatment outcome in HIV-HBV co-infected adolescents receiving tenofovir-containing ARV regimen
$5,230

Romanee Chaivarith, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data
$23,990

Tavitiya Sudjaritruk, MD, ScM, PhD
TREAT Asia Pediatric HIV Observational Database (TAP-HOD)
$15,000

Treat Asia Pediatric HIV Observational Database (TAP-HOD)

Treat Asia Pediatric HIV Observational Database (TAP-HOD)
Peripheral Arterial Diseases among Perinatally HIV-infected Thai Adolescents (PAD study) $18,423

Chiangrai Prachanukroh Hospital
Chiang Rai
Raiwan Hansudewechakul, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) $15,000

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia $64,043

Study of Transitioning Asian Youth (STAY) Cohort $21,690

Pacharee Kantipong, MD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data $30,040

HIV-NAT / Thai Red Cross AIDS Research Centre
Bangkok
Praphan Phanuphak, MD, PhD
Examining the prevalence rate and determinants of frailty in the HIV positive and negative Thai populations $2,545

Anchalee Avihingsanon, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,280

Sivaporn Gatechompol, MD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia $65,687

Watsamon Jantarabenjakul, MD
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents $4,974

Stephen Kerr, PhD
Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI (data management center) $9,000

Study of Transitioning Asian Youth (STAY) Cohort Statistical Analysis Center $18,038

Nittaya Phanuphak, MD, PhD
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia (central lab and data manager) $223,151

Neovaginal and anal HPV and related diseases among post-operative transgender women $35,455

Wasana Prasitsuebsai, MD, MPH
Coordinating Center: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children $32,075

Thanyawee Puthanakit, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) $15,000

Peripheral Arterial Diseases among Perinatally HIV-infected Thai Adolescents $13,402

Kiat Ruxuntham, MD
Effectiveness and tolerability of HCV treatment in HIV co-infected patients: Treatment $11,421

Thai Red Cross AIDS Research Centre
Bangkok
Tarandee Anand
The impact of online interventions on the HIV prevention/treatment cascade among MSM and transgender individuals $21,600

Thanyawee Puthanakit, MD
Supporting HIV-infected Adolescents and Youth in Achieving Successful Transition to Adult Care $30,000

Mahidol University by Faculty of Medicine Siriraj Hospital
Kulkanya Chokephaibulkit, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) $15,000

Understanding adherence, stigma, and behavioral risk factors of adolescents in TApHOD using ACASI $2,765

Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia $49,839

Study of Transitioning Asian Youth (STAY) Cohort $24,958

Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents $14,996

Ramathibodi Hospital, Mahidol University
Sasisopin Kiertiburanakul, MD, MHS
TREAT Asia HIV Observational Database (TAHOD) including NCD Data $23,150

Srinagarind Hospital, Khon Kaen University
Khon Kaen
Pope Kosalaraksa
Treatment switch from efavirenz to rilpivirine in virologically-suppressed HIV-infected Thai adolescents $12,621

Pagakrong Lumbiganon, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) $8,100

Study of Transitioning Asian Youth (STAY) Cohort $21,251

USA
Massachusetts General Hospital
Boston, MA
Andrea Ciaranello, MD, MPH
Estimating the magnitude of the pediatric and adolescent HIV epidemic in Thailand $59,951

VIETNAM
Bach Mai Hospital
Hanoi
Do Duy Cuong, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,720

Resistance to Second-line Antiretroviral Therapy in HIV-Infected Adults in Asia (TASER-2) $11,978

Children’s Hospital 1
Ho Chi Minh City
Tran Ngoc Hanh Dan, MD, MSc
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia $8,777

Children’s Hospital 2
Ho Chi Minh City
Do Chau Viet, MD
TREAT Asia Pediatric HIV Observational Database (TApHOD) $20,000

Hung Vuong Hospital
Ho Chi Minh City
Dang Le Dung Hanh, MA
Human Papillomavirus Infection in Perinatally HIV-infected Adolescents in Asia $13,337

National Hospital of Pediatrics
Hanoi
Nguyen Van Lam, MD, MSc
TREAT Asia Pediatric HIV Observational Database (TApHOD) $20,000

Study of Transitioning Asian Youth (STAY) Cohort $8,791

National Hospital of Tropical Diseases
Hanoi
Nguyen Van Kinh, MD, PhD
TREAT Asia HIV Observational Database (TAHOD) including NCD Data $22,610

Resistance to Second-line Antiretroviral Therapy in HIV co-infected patients: Treatment $9,023

Vietnam Network of People Living with HIV (VNP+)
Hanoi
Do Dang Dong
Increase knowledge about HCV diagnosis, and care and treatment access in the PLHIV and PWID community $6,500
All projects listed below were awarded amfAR funding for the period October 1, 2015, through September 30, 2016.

**AMFAR HIV SCHOLARS AWARDS**

**Designing trans-community led HIV treatment counseling programs suitable for the needs of trans populations in South Africa**
Principal Investigator: Liesl Theron
Gender DynamiX
Cape Town, South Africa
$25,000

**Pilot study on HIV among men who have sex with men in Belize**
Principal Investigator: Erika Castellanos
Collaborative Network of Persons Living with HIV (C-NET+)
Belize City, Belize
$25,000

**Assessing the efficacy of online HIV home testing support service to increase quarterly HIV testing among MSM**
Principal Investigator: Weibin Cheng
GZTZ.ORG
Guangzhou, China
$25,000

**Identifying barriers in accessing care services for low-adherence to ART by MSM and transgender populations in Pakistan**
Principal Investigator: Sheryar Kazi
NAZ Male Health Alliance
Lahore, Pakistan
$25,000

**GENERAL GMT INITIATIVE GRANTS AND AWARDS**

**A training program for HIV research among MSM in low- and middle-income countries**
Project Director: Ronald D. Stall, PhD, MPH
University of Pittsburgh
Pittsburgh, PA
$164,000

The projects listed below were awarded amfAR funding during the period October 1, 2015, through September 30, 2016.

**UNITED STATES**

**Evaluation of needle exchange distribution policy**
Project Director: Susan Sherman, PhD
Johns Hopkins University
Baltimore, MD
$60,000

**Improving the health of young black men who have sex with men (MSM)**
Project Director: Jeffrey Crowley
Georgetown University
Washington, DC
$99,350

**PrEP advocacy and demand creation for MSM**
Project Director: Emily Bass
AIDS Vaccine Advocacy Coalition (AVAC)
New York, NY
$50,600

**Developing local strategies to implement safe injection facilities (SIFs)**
Project Director: Emily Mariko-Sanders
Project Inform
San Francisco, CA
$10,000

**INTERNATIONAL**

**Increasing access to services for PLHIV who use drugs in the Philippines**
Project Director: Cara O’Connor
Sustained Health Initiatives of the Philippines
Mandaluyong City, Philippines
$30,000
### Financial Highlights

**For the year ended September 30, 2016**

**Public Support and Revenue**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support</td>
<td>$7,104,647</td>
</tr>
<tr>
<td>Special events</td>
<td>22,840,383</td>
</tr>
<tr>
<td>Planned giving</td>
<td>4,995,589</td>
</tr>
<tr>
<td>Government funding</td>
<td>13,063,451</td>
</tr>
<tr>
<td>Investment income and other revenue</td>
<td>2,535,019</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td>$50,539,089</td>
</tr>
</tbody>
</table>

**Expenses**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$20,306,002</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>5,276,103</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>1,737,688</td>
</tr>
<tr>
<td>Public Policy</td>
<td>2,162,183</td>
</tr>
<tr>
<td>Public Information</td>
<td>3,892,270</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td>$33,374,246</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>6,054,303</td>
</tr>
<tr>
<td>Management and general</td>
<td>2,509,982</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td>$8,564,285</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total expenses</strong></td>
<td>$41,938,531</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change in net assets</td>
<td>8,600,558</td>
</tr>
<tr>
<td>Net assets, beginning of year</td>
<td>53,038,622</td>
</tr>
<tr>
<td><strong>Net assets, end of year</strong></td>
<td>$61,639,180</td>
</tr>
</tbody>
</table>

### Statement of Financial Position

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments</td>
<td>$64,039,115</td>
</tr>
<tr>
<td>Pledges and receivables, net</td>
<td>10,460,976</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>3,297,004</td>
</tr>
<tr>
<td>Furniture, equipment, and leasehold improvements, net</td>
<td>2,976,566</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$80,773,661</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$3,412,592</td>
</tr>
<tr>
<td>Grants and fellowships payable, net</td>
<td>2,973,966</td>
</tr>
<tr>
<td>Deferred support and refundable advances</td>
<td>10,727,662</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>2,020,261</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>$19,134,481</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total net assets</strong></td>
<td>61,639,180</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$80,773,661</td>
</tr>
</tbody>
</table>
### Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$6,054,303</td>
</tr>
<tr>
<td>Management and general</td>
<td>$2,509,982</td>
</tr>
<tr>
<td>Program</td>
<td>$33,374,246</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$41,938,531</strong></td>
</tr>
</tbody>
</table>

### Program Expenses

<table>
<thead>
<tr>
<th>Program</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$20,306,002</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>$5,276,103</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>$1,737,688</td>
</tr>
<tr>
<td>Public Policy</td>
<td>$2,162,183</td>
</tr>
<tr>
<td>Public Information</td>
<td>$3,892,270</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$33,374,246</strong></td>
</tr>
</tbody>
</table>
Chairman of the Board
Kenneth Cole
Chairman
Kenneth Cole Productions
New York, NY

Founding Chairman
Mathilde Krim, Ph.D.
Adjunct Professor
Mailman School of Public Health
Columbia University
New York, NY

Vice Chairman
Patricia J. Matson
Senior Vice President, Communications (ret.)
ABC, Inc.
New York, NY

Vice Chairman and Treasurer
John C. Simons
Managing Partner
Corporate Fuel Partners, LLC
New York, NY

Secretary
Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates
Crockett, CA

TRUSTEES

Arlen H. Andelson
Senior Partner (ret.)
Andelson & Andelson
Los Angeles, CA

Harry Belafonte
President
Belafonte Enterprises, Inc.
New York, NY

David Bohnett
Chairman
David Bohnett Foundation
Beverly Hills, CA

Zev Braun
President and CEO
Braun Entertainment Group, Inc.
Beverly Hills, CA

Jonathan S. Canno
New York, NY

Donald A. Capoccia
Managing Principal
BFC Partners
Brooklyn, NY

R. Martin Chavez, Ph.D.
Chief Information Officer
The Goldman Sachs Group, Inc.
New York, NY

Jane B. Eisner
President
The Eisner Foundation
Bel Air, CA

T. Ryan Greenawalt
Managing Director
Ramirez & Co.
President
Harrison Street Productions
New York, NY

Regan Hofmann
Policy Officer
U.S. Liaison Office
UNAIDS
Washington, D.C.

Michael J. Klingensmith
Publisher and CEO
Star Tribune
Minneapolis, MN

Kevin McClatchy
Chairman of the Board
The McClatchy Company
Ligonier, PA

Michele V. McNeill, Pharm.D.
Chairman
McNeill Family Foundation
Sarasota, FL

Edward L. Milstein
Co-Chairman, Milford Management
Co-Chairman, Emigrant Savings Bank
Partner, Milstein Properties
New York, NY

Cindy D. Rachofsky
Philanthropist
Dallas, TX

Vincent A. Roberti
Chairman, Roberti Global, LLC
Managing Director, Roberti Associates Global, LLC
Washington, D.C.

Bill Roedy
London, UK

Raymond F. Schinazi, Ph.D., D.Sc.
Frances Winship Walters Professor of Pediatrics
Director, Laboratory of Biochemical Pharmacology
Emory University
Decatur, GA

Alan D. Schwartz
Executive Chairman
Guggenheim Partners, LLC
New York, NY

Diana L. Taylor
Vice Chair
Solera Capital, LLC
New York, NY

TRUSTEE EMERITUS

Arthur J. Armman, M.D.
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

Dame Elizabeth Taylor
Founding International Chairman

Sheldon W. Andelson, Esq.
Arnold W. Klein, M.D.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, M.D.
Peter Scott, Esq.
Tom Stoddard
Joel D. Weisman, D.O.

SPECIAL APPOINTMENTS

Global Campaign Chair
Sharon Stone

Global Fundraising Chairman
Milutin Gatsby

amfAR AMBASSADORS

Cheyenne Jackson
Janet Jackson
Milla Jovovich
Liza Minnelli
Michelle Yeoh

COMMITTEES OF THE BOARD OF TRUSTEES

Executive
Kenneth Cole, Chair
Mathilde Krim, Ph.D.
Patricia J. Matson
Michael J. Klingensmith

Audit
John Simons, Chair
R. Martin Chavez, Ph.D.
T. Ryan Greenawalt

Board Development
Donald A. Capoccia, Co-Chair
Patricia J. Matson, Co-Chair
Arlen Andelson
Bill Roedy
Mervyn F. Silverman, M.D., M.P.H.

Communications/Social Media/Marketing
Regan Hofmann, Chair
Kenneth Cole
T. Ryan Greenawalt
Patricia J. Matson
Kevin McClatchy
Vincent A. Roberti
Bill Roedy

Compensation and Organizational Development
John C. Simons, Chair
Michael J. Klingensmith
Kevin McClatchy
Dennis R. Burton, Ph.D.
Professor
Department of Immunology
The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.
Chief Science Officer
Scripps CHAVI-ID
The Scripps Research Institute

Edward Campbell, Ph.D.
Assistant Professor
Department of Microbiology and Immunology
School of Medicine
Loyola University at Chicago

Alex Carballo-Diepguez, Ph.D.
Co-Director and Senior Research Scientist
HIV Center for Clinical and Behavioral Studies
New York State Psychiatric Institute
Columbia University

Nicolas Chomont, Ph.D.
Assistant Professor
Microbiology and Immunology
Université de Montréal, Centre de Recherche du CHUM

David B. Clifford, M.D.
Professor
Department of Neurology
Washington University School of Medicine

C. Budd Colby, Ph.D.
Principal
Colby Biomedical Ventures

Grant Colfax, M.D.
Director
Marin Health and Human Services
San Rafael, California

Elizabeth Connick, M.D.
Professor of Medicine
Chief, Division of Infectious Diseases
Department of Medicine
University of Arizona

Deborah Jean Cotton, M.D., M.P.H.
Professor of Medicine
Boston University School of Medicine

Bryan R. Cullen, Ph.D., D.Sc.
James B. Duke Professor
Department of Molecular Genetics and Microbiology
Director, Duke University Center for Virology
Duke University Medical Center

Susanna Cunningham-Rundies, Ph.D.
Professor Emerita of Research Immunology
Department of Pediatrics
Weill Cornell Medical College

Richard Thomas D’Aquila, M.D.
The Howard Taylor Ricketts Professor of Medicine
Division of Infectious Diseases
Director, Northwestern HIV Translational Research Center
Feinberg School of Medicine
Northwestern University

Steven Deeks, M.D.
Professor
Department of Medicine
University of California, San Francisco

Sherry Deren, Ph.D.
Co-Director
Center for Drug Use and HIV Research
New York University College of Nursing

Roger Detels, M.D., M.S.
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.
Director
Division of AIDS (DAIDS)
National Institute of Allergy and Infectious Diseases
National Institutes of Health

D. Peter Drotman, M.D., M.P.H.
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.
Director
Division of Gender, Sexuality, & Health
Program for the Study of LGBT Health
NYS Psychiatric Institute/Columbia University

Jacob Estes, Ph.D.
Principal Scientist/Principal Investigator
AIDS and Cancer Virus Program (ACVP)
Frederick National Laboratory for Cancer Research
National Cancer Institute

Homayaon Farzadegan, Ph.D.
Professor
Department of Epidemiology
Johns Hopkins Bloomberg School of Public Health

Dianne M. Finkelstein, Ph.D.
Professor of Biostatistics
Harvard School of Public Health
Director of the Center for Biostatistics
Massachusetts General Hospital

Gerald Herbert Friedland, M.D.
Professor and Director
AIDS Care Program
Department of Internal Medicine
Yale School of Medicine

Rémi Fromentin, Pharm.D., Ph.D.
Postdoctoral Researcher
Université de Montréal, Centre de Recherche du CHUM

Howard E. Gendelman, M.D.
Professor and Chair, Department of Pharmacology and Experimental Neuroscience
Margaret R. Larson Professor of Internal Medicine and Infectious Diseases
Director, Center for Neurodegenerative Disorders
University of Nebraska Medical Center

Nancy L. Haigwood, Ph.D.
Director and Senior Scientist
Division of Pathobiology and Immunology
Oregon National Primate Research Center
Oregon Health and Science University

Timothy Henrich, M.D.
Assistant Professor of Medicine
Division of Infectious Disease
University of California, San Francisco

Charles H. Hinkin, Ph.D.
Professor
Department of Psychiatry and Biobehavioral Sciences
David Geffen School of Medicine
University of California, Los Angeles

David Ho, M.D.
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center
Thomas J. Hope, Ph.D.
Professor
Department of Cell and Molecular Biology
Feinberg School of Medicine
Northwestern University

Shiu-Lok Hu, Ph.D.
Professor
School of Pharmacy
University of Washington

Jonathan Kars, Ph.D.
Director
Center for AIDS Research
Case Western Reserve University

Vineet KewalRamani, Ph.D.
Chief, Model Development Section
HIV Drug Resistance Program
National Cancer Institute
National Institutes of Health

Hans-Peter Kiem, M.D., F.A.C.P.
Full Member, Clinical Research Division
Jose Carreras/E. Donnall Thomas Endowed Chair for Cancer Research
Fred Hutchinson Cancer Research Center
Seattle, WA

Scott Kitchen, Ph.D.
Assistant Professor of Medicine
Division of Hematology and Oncology
David Geffen School of Medicine
University of California, Los Angeles

Richard Kornbluth, M.D., Ph.D.
President and Chief Scientific Officer
Multimeric Biotherapeutics, Inc.

Richard A. Koup, M.D.
Deputy Director, Vaccine Research Center
Chief, Immunology Laboratory
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Nathaniel R. Landau, Ph.D.
Professor
Department of Microbiology
New York University School of Medicine

Alan L. Landay, Ph.D.
Professor and Chairman
Department of Immunology and Microbiology
Rush-Presbyterian-St. Luke’s Medical Center

Michael Lederman, M.D.
Scott R. Inkey Professor of Medicine
Associate Director, Center for AIDS Research
Case Western Reserve University

Tun-Hou Lee, D.Sc.
Professor of Virology, Emeritus
Department of Immunology and Infectious Diseases
Harvard School of Public Health

Michael J. Leibowitz, M.D., Ph.D.
Professor, Medical Microbiology and Immunology
University of California, Davis

Robert J. Levine, M.D.
Professor of Medicine
Center for Interdisciplinary Research on AIDS
Yale University

Sharon Lewin, F.R.A.C.P., Ph.D.
Director
Peter Doherty Institute for Infection and Immunity
University of Melbourne

Mathias Lichterfeld, M.D.
Assistant Professor of Medicine
Massachusetts General Hospital

Judy Lieberman, M.D., Ph.D.
Senior Investigator
Immune Disease Institute
Professor of Pediatrics
Harvard Medical School

H. Kim Lyerly, M.D.
Professor in Surgery, Immunology, Pathology
George Barth Geller Chair of Cancer Research
Director of the Center of Applied Therapeutics
Duke Cancer Institute
Duke University Medical Center

Frank Maldarelli, M.D., Ph.D.
Investigator
HIV DRP Host-Virus Interaction Branch
National Cancer Institute
National Institutes of Health

David M. Margolis, M.D.
Professor of Medicine, Microbiology and Immunology, and Epidemiology
School of Medicine
University of North Carolina at Chapel Hill

Martin H. Markowitz, M.D.
Professor and Clinical Director
Aaron Diamond AIDS Research Center

Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Joseph M. McCune, M.D., Ph.D.
Professor of Medicine
Chief, Division of Experimental Medicine
University of California, San Francisco

Donna Mildvan, M.D.
Chief, Division of Infectious Diseases
Department of Medicine
Beth Israel Medical Center

Jay A. Nelson, Ph.D.
Professor and Director
Vaccine and Gene Therapy Institute
Oregon Health and Science University

Una O’Doherty, M.D., Ph.D.
Associate Professor
Department of Pathology and Laboratory Medicine
Perelman School of Medicine
University of Pennsylvania

Nancy Padman, Ph.D., M.P.H.
Adjunct Professor of Epidemiology
School of Public Health
University of California, Berkeley

Savita Pahwa, M.D.
Professor of Microbiology and Immunology
Professor in Pediatrics and Medicine
Director of the Miami Center for AIDS Research
University of Miami Leonard M. Miller School of Medicine

Tristram G. Parslow, M.D., Ph.D.
William Patterson Timmie Professor and Chair
Department of Pathology and Laboratory Medicine
Emory University School of Medicine

Matija Peterlin, M.D.
Professor of Medicine, Microbiology and Immunology
Department of Medicine
University of California, San Francisco

Lynn Pulliam, Ph.D.
Professor
Department of Laboratory Medicine and Medicine
University of California, San Francisco
Veterans Affairs Medical Center

Lee Ratner, M.D., Ph.D.
Professor
Department of Medicine
Washington University School of Medicine

Andrew Rice, Ph.D.
Professor
Department of Molecular Virology and Microbiology
Baylor College of Medicine

Charles Rinaldo, Ph.D.
Senior Scientist and Director of Biomedical HIV Research
Center for Biomedical Research
Population Council

Ruth M. Ruprecht, M.D., Ph.D.
Scientist, Department of Virology and Immunology
Southwest National Primate Research Center
Director, Texas Biomed AIDS Research Program
Texas Biomedical Research Institute

Sarah Schlesinger, M.D.
Associate Professor of Clinical Investigation
Laboratory of Molecular Immunology
The Rockefeller University

Frederick A. Schmitt, Ph.D.
Professor
Departments of Neurology, Psychiatry, and Psychology and Behavioral Science
Sanders Brown Center on Aging
University of Kentucky

Gerald Schochetman, Ph.D.
Senior Director, Diagnostics Research
Abbott Laboratories

Robert Turner Schooley, M.D.
Academic Vice Chair
Professor and Head
Department of Medicine/Division of Infectious Diseases
University of California, San Diego
Gail Skowron, M.D.
Professor of Medicine
Boston University School of Medicine

Serena Spudich, M.D., M.A.
Associate Professor of Neurology
Division Chief, Neurological Infections and Global Neurology
Department of Neurology
Yale School of Medicine

Leonidas Stamatatos, Ph.D.
Member
Fred Hutchinson Cancer Research Center
Vaccine and Infectious Disease Division
Immunology and Vaccine Development Program
Seattle, WA

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Susana Valente, Ph.D.
Associate Professor
Department of Immunology and Microbial Sciences
The Scripps Research Institute

Barbara Visscher, M.D., Dr.P.H.
Professor of Epidemiology
University of California, Los Angeles

David Vlahov, Ph.D., R.N.
Professor of Nursing, Epidemiology, and Biostatistics
University of California, San Francisco

David J. Volsky, Ph.D.
Professor of Medicine and Pathology
Icahn School of Medicine at Mount Sinai

Steven S. Witkin, Ph.D.
Professor of Immunology
Department of Obstetrics and Gynecology
Weill Cornell Medical College

Peter R. Wolfe, M.D.
Associate Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles

Steven Wolinsky, M.D.
Professor
Medicine/Infectious Diseases
Feinberg School of Medicine
Northwestern University

Richard T. Wyatt, Ph.D.
Professor of Immunology
IAVI Center for Neutralizing Antibodies
The Scripps Research Institute

Jerome Zack, Ph.D.
Professor
Department of Medicine
David Geffen School of Medicine
University of California, Los Angeles

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates
Crockett, CA

Judith D. Auerbach, Ph.D.
Science and Policy Consultant and Professor
School of Medicine
University of California, San Francisco

David Bloom, Ph.D.
Clarence James Gamble Professor of Economics and Demography
Department of Global Health and Population
Harvard School of Public Health
Boston, MA

Tim Brown, Ph.D.
Senior Fellow
The East-West Center
Honolulu, HI

Daniel Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health

Daria J. Hazuda, Ph.D.
Vice President, Scientific Affairs for Infectious Disease
Merck & Company, Inc.
West Point, PA

Kenneth Hugh Mayer, M.D.
Infectious Disease Attending & Director of HIV Prevention Research
Beth Israel Deaconess Medical Center

Professor of Medicine
Harvard Medical School

Medical Research Director, Co-Chair
The Fenway Institute/Fenway Health

Mario Stevenson, Ph.D.
Professor of Medicine
Chief, Division of Infectious Diseases
University of Miami Leonard M. Miller School of Medicine

Jeffrey L. Sturchio, Ph.D.
Senior Partner
Rabin Martin
New York, NY

Visiting Scholar
The Institute for Applied Economics, Global Health and the Study of Business Enterprise
Johns Hopkins University

Member
The Council on Foreign Relations
Washington, D.C.

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.
Vice President and General Counsel

Gregorio Millett, M.P.H.
Vice President and Director, Public Policy

Eric Muscatell
Vice President, Development

AnnMari Shannahan
Vice President, Public Information

Phill Wilson
Chief Executive Officer and President
The Black AIDS Institute
Los Angeles, CA
amfAR, The Foundation for AIDS Research

NEW YORK
120 Wall Street, 13th Floor
New York, NY 10005-3908
(212) 806-1600 (tel)
(212) 806-1601 (fax)

WASHINGTON, D.C.
1100 Vermont Avenue, NW
Suite 600
Washington, DC 20005
(202) 331-8600 (tel)
(202) 331-8606 (fax)

BANGKOK, THAILAND
TREAT Asia
Exchange Tower
388 Sukhumvit Road, Suite 2104
Klongtoey, Bangkok 10110
Thailand
+66 (0)2 663 7561 (tel)
+66 (0)2 663 7562 (fax)

www.amfar.org